Compare GME & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GME | JAZZ |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Electronics Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.4B |
| IPO Year | 2005 | 2007 |
| Metric | GME | JAZZ |
|---|---|---|
| Price | $22.17 | $232.14 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $13.50 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 9.2M | 873.1K |
| Earning Date | 06-09-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.33 | N/A |
| EPS | 0.77 | ★ 4.43 |
| Revenue | ★ $3,629,900,000.00 | $1,618,693,000.00 |
| Revenue This Year | $18.98 | $6.22 |
| Revenue Next Year | N/A | $7.68 |
| P/E Ratio | ★ $29.19 | $51.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.94 | $105.00 |
| 52 Week High | $35.81 | $230.40 |
| Indicator | GME | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 74.47 |
| Support Level | $20.43 | $128.87 |
| Resistance Level | $23.10 | N/A |
| Average True Range (ATR) | 1.16 | 5.99 |
| MACD | -0.36 | 2.07 |
| Stochastic Oscillator | 3.47 | 92.17 |
GameStop Corp offers games, collectibles, and entertainment products through its stores and ecommerce platforms. Its products include Hardware and accessories offering new and pre-owned gaming platforms from the console manufacturers, Software offering new and pre-owned gaming software for current and certain prior generation consoles and sell a wide range of in-game digital currency, digital downloadable content and full-game downloads, and Collectibles consist of apparel, toys, trading cards, gadgets and other retail products for pop culture and technology enthusiasts and collectibles related services, such as submission services for the authentication and grading of trading cards. The company operates its business in three geographic segments: the United States, Australia, and Europe.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.